Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
Meletios A. Dimopoulos
,
Meral Beksac
,
Vladimir Vorobyev
,
PAWEŁ ROBAK
,
Kazuhito Suzuki
,
Jodie Wilkes
,
Simon Mcnamara
,
Amy Phillips-Jones
,
Kristin Morris
,
Farrah Pompilus
,
Molly Purser
,
Neal Sule
,
Brandon Kremer
,
Angely Loubert
,
Laurine Bunod
,
Manal M'Hari
,
Xiaoou L Zhou
,
Giulia Fulci
,
María-Victoria Mateos
,
Suzanne Trudel
,
Aaron Ronson
,
Adrian Alegre Amor
,
Alberto Eterio Velasco Valdazo
,
Amos Cohen
,
Andrew Lim
,
Anna Sureda Balari
,
Antonia Sampol Mayol
,
Aristeidis Chaidos
,
Artur Jurczyszyn
,
Aurore Perrot
,
Bradley Augustson
,
Britta Besemer
,
Cecily Forsyth
,
Celia Suriu
,
Chang-Ki Min
,
Cindy Lee
,
Clifton Mo
,
Dmitriy Kirtbaya
,
Edwin Lee
,
Hatzimichael Eleftheria
,
Esin Oguz Kozan
,
Esther Gonzalez Garcia
,
Estrella Carrillo Cruz
,
Felipe de Arriba de la Fuente
,
Guldane Cengiz Seval
,
Guner Ozsan
,
Guray Saydam
,
Hang Quach
,
Hanlon Sia
,
Hannah Hunter
,
Hiroshi Handa
,
Hyeon‐Seok Eom
,
Ian Irving
,
Igor Davydkin
,
Inna Tsoran-Rosenthal
,
Irit Avivi
,
Iurii Osipov
,
Ivan Spicka
,
Ja Min Byun
,
Jaehoon Lee
,
Jakub Radocha
,
Jaroslaw Czyz
,
Javier De La Rubia Comos
,
Je Jung Lee
,
Jean-Marc Schiano De Colella
,
Jesus Berdeja
,
Jin Seok Kim
,
Jock Simpson
,
Johnny Francisco Cordeiro Camargo
,
Kaichi Nishiwaki
,
Kamaraj Karunanithi
,
Kathryn Forwood
,
Kazutaka Sunami
,
Keith Fay
,
Kevin Boyd
,
Kihyun Kim
,
Koji Kawamura
,
Konstantinos Anargyrou
,
Kosei Matsue
,
Laura Maria Fogliatto
,
Laura Rosiñol Dachs
,
Ludek Pour
,
Magdalena Dutka
,
MANUEL MODIANO
,
Marcelo Pitombeira De Lacerda
,
Maria Del Carmen Martinez Chamorro
,
Maria Victoria Mateos Manteca
,
Marie Hughes
,
Markus Munder
,
Martin Kortuem
,
Matteo Claudio Da Via
,
Matthew Jenner
,
MAURIZIO MARTELLI
,
Mehmet Sinan Dal
,
Mehmet Turgut
,
Dimopoulos Meletios Athanasios
,
Melita Kenealy
,
Mercedes Gironella Mesa
,
Merit Hanna
,
Michail Iskas
,
Michele Cavo
,
Nicole Chien
,
Olga Uspenskaya
,
Osnat Jarchowsky
,
Paula Rodriguez Otero
,
Pierre Feugier
,
Sergey Voloshin
,
Sergey Semochkin
,
Sharon Jackson
,
Shigeki Ito
,
Shinsuke Iida
,
Silvia Mangiacavalli
,
Sosana Delimpasi
,
Suman Kambhampati
,
Syed Zafar
,
Tadeusz Robak
,
Takayuki Ikezoe
,
Tomasz Wrobel
,
Vânia Tietsche De Moraes Hungria
,
Vera Zherebtsova
,
Vidya Mathavan
,
Wei Yang
,
Xin Du
,
Yulya Dyachkova
,
Zafer Gulbas
,
Zubeyde Ozkurt
Publication type: Journal Article
Publication date: 2025-11-05
scimago Q1
wos Q1
SJR: 4.936
CiteScore: 23.8
Impact factor: 17.7
ISSN: 23523026
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
1
Total citations:
1
Citations from 0:
0
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Dimopoulos M. A. et al. Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial // The Lancet Haematology. 2025. Vol. 12. No. 11. p. e876-e886.
GOST all authors (up to 50)
Copy
Dimopoulos M. A. et al. Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial // The Lancet Haematology. 2025. Vol. 12. No. 11. p. e876-e886.
Cite this
RIS
Cite this
BibTex (up to 50 authors)
Copy
@article{2025_Dimopoulos,
author = {Meletios A. Dimopoulos and Meral Beksac and Vladimir Vorobyev and PAWEŁ ROBAK and Kazuhito Suzuki and Jodie Wilkes and Simon Mcnamara and Amy Phillips-Jones and Kristin Morris and Farrah Pompilus and Molly Purser and Neal Sule and Brandon Kremer and Angely Loubert and Laurine Bunod and Manal M'Hari and Xiaoou L Zhou and Giulia Fulci and María-Victoria Mateos and Suzanne Trudel and Aaron Ronson and Adrian Alegre Amor and Alberto Eterio Velasco Valdazo and Amos Cohen and Andrew Lim and Anna Sureda Balari and Antonia Sampol Mayol and Aristeidis Chaidos and Artur Jurczyszyn and Aurore Perrot and Bradley Augustson and Britta Besemer and Cecily Forsyth and Celia Suriu and Chang-Ki Min and Cindy Lee and Clifton Mo and Dmitriy Kirtbaya and Edwin Lee and Hatzimichael Eleftheria and Esin Oguz Kozan and Esther Gonzalez Garcia and Estrella Carrillo Cruz and Felipe de Arriba de la Fuente and Guldane Cengiz Seval and Guner Ozsan and Guray Saydam and Hang Quach and Hanlon Sia and Hannah Hunter and others},
title = {Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial},
journal = {The Lancet Haematology},
year = {2025},
volume = {12},
publisher = {Elsevier},
month = {nov},
url = {https://linkinghub.elsevier.com/retrieve/pii/S235230262500256X},
number = {11},
pages = {e876--e886},
doi = {10.1016/s2352-3026(25)00256-x}
}
Cite this
MLA
Copy
Dimopoulos, Meletios A., et al. “Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.” The Lancet Haematology, vol. 12, no. 11, Nov. 2025, pp. e876-e886. https://linkinghub.elsevier.com/retrieve/pii/S235230262500256X.